antibiotics

an Open Access Journal by MDPI

IMPACT FACTOR 4.3

Indexed in: PubMed

CITESCORE 7.3

Microbiological and Clinical Aspects of *Actinomyces* Infections

Guest Editors:

Prof. Dr. Edit Urbán
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Pécs, Hungary

Dr. Mário Gajdács
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, 6720 Szeged, Hungary

Deadline for manuscript submissions:
closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

Actinomyces species are anaerobic, non-spore-forming Gram-positive rods that are important saprophytic constituents of the normal microbiota of humans, with highest numbers in the oropharynx. *Actinomyces* species are considered as low-grade pathogens. *Actinomyces* infections (actinomycoses) are considered to be rare, their true prevalence may be underestimated. Additonally, diagnosis of actinomycosis may be difficult as the clinical presentation of symptoms and signs can mimic other pathologies. MALDI-TOF MS has allowed for the correct and precise identification of anaerobes in a clinically-relevant time frame, compared to conventional, biochemical methods.

The purpose of this issue is to enrich the existing literature regarding this neglected pathogen, therefore manuscripts including but not limited to the following topics are welcome: vaulable case reports and novel results on the epidemiology, diagnostics, clinical features and therapy of actinomycoses, in addition to experimental findings on the virulence factors and resistace determinants of *Actinomyces* spp.

Keywords: *Actinomyces* spp; cervicofacial infections; thoracic infections; abdominal infections

antibiotics

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 7.3

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
𝕏@antibioticsmdpi